rheumatoid arthritis(RA)
Conditions
Interventions
dose maintain group: no change of treatment
MTX reducing group: reduce 2mg/week of MTX at ever 8 weeks. If remission is maintained at MTX 2mg/week, MTX will be stopped.
ADA spacing group: space th
Sponsors
Keio University School of Medicine, Japan.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) the RA patients comfortable for the 1987 ACR RA classification criteria or 2010 ACR/EULAR RA classification criteria. 2) the patients who are maintaining RA crinical remission(DAS28<2.6) with MTX and 40mg/2weeks of ADA during 6 month. 3) the patients who agree this study after sufficient informed consent.
Exclusion criteria
Exclusion criteria: 1) the patient who are assessed unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTX reducing group: last MTX dose ADA spacing group: last intervals of ADA | — |
Secondary
| Measure | Time frame |
|---|---|
| at 48 weeks) the rate of maintain of DAS28<2.6 the possibility of MTX reducing and stopping the possibility of ADA spacing and stopping the concentration of MTX-PG the transition of disease activity | — |
Countries
Japan
Contacts
Public ContactYuko Kaneko
Keio University School of Medicine, Japan. Division of Rheumatology, Department of Internal Medicine,
Outcome results
None listed